An old drug for a common disease
- 1Cochrane Neurological Field, c/o Direzione salute, coesione sociale e società della conoscenza, Regione Umbria, Perugia, Italy
- 2Department of Neurology, Royal Perth Hospital, Perth, Australia
- 3Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, Midlothian, UK
- Correspondence to Dr Teresa Anna Cantisani, Cochrane Neurological Field, c/o Direzione salute, coesione sociale e società della conoscenza, Regione Umbria, Perugia, Italy;
- Received 18 September 2012
- Revised 2 November 2012
- Accepted 5 November 2012
- Published Online First 12 December 2012
Migraine is a common and frequently incapacitating neurological disease highly prevalent in people of working age, especially women.
For this reason, a paper1 that summarises and highlights a systematic review that considers Aspirin, an old, inexpensive and easy to acquire drug, with or without metoclopramide, is well received.2
The paper provides an organised picture of the published trials on this topic, and it also gives a good estimation of the efficacy and safety of this drug. However, the results are dependent on synthesised outcome measures that, in some cases, are not extremely relevant (pain-free at 2 h or precise use of rescue medication) from the patient's point of view.
According to the WHO, migraine alone is 19th among all causes of years lived with disability worldwide. Repeated headache attacks, and the constant fear of the next episode often impinges on family and social life, and on employment.
Nowadays, there is the potential for most migraine …